Abstract
Minocycline, the 7-dimethylamino- 6-dimethyl-desoxytetracycline hydrochloride, is a caspase-1 inhibitor and may serve as anti-apoptotic agent, thereby acting neuroprotective. It directly inhibits both caspase-independent and -dependent mitochondrial cell death pathways, and decreases inducible nitric oxide synthetase activity. Minocycline delays disease progression in the transgenic mouse model of Huntington;s disease (HD), extending survival by 14%. HD is a late onset relentlessly progressive, neurodegenerative disorder with currently no cures or even effective therapies, death occurring 15 years after onset. In this review, recent clinical and preclinical data on minocycline in HD and neuroprotective alternatives discussed.
Keywords: neurodegenerative disorder, gliosis, highly unsaturated fatty acids, glutamate, nmda-receptor antagonist, gabaergic neurotransmission
Letters in Drug Design & Discovery
Title: Neuroprotection in Huntington;s Disease
Volume: 2 Issue: 2
Author(s): Raphael M. Bonelli, Anna K. Hodl and Hans-Peter Kapfhammer
Affiliation:
Keywords: neurodegenerative disorder, gliosis, highly unsaturated fatty acids, glutamate, nmda-receptor antagonist, gabaergic neurotransmission
Abstract: Minocycline, the 7-dimethylamino- 6-dimethyl-desoxytetracycline hydrochloride, is a caspase-1 inhibitor and may serve as anti-apoptotic agent, thereby acting neuroprotective. It directly inhibits both caspase-independent and -dependent mitochondrial cell death pathways, and decreases inducible nitric oxide synthetase activity. Minocycline delays disease progression in the transgenic mouse model of Huntington;s disease (HD), extending survival by 14%. HD is a late onset relentlessly progressive, neurodegenerative disorder with currently no cures or even effective therapies, death occurring 15 years after onset. In this review, recent clinical and preclinical data on minocycline in HD and neuroprotective alternatives discussed.
Export Options
About this article
Cite this article as:
Bonelli M. Raphael, Hodl K. Anna and Kapfhammer Hans-Peter, Neuroprotection in Huntington;s Disease, Letters in Drug Design & Discovery 2005; 2 (2) . https://dx.doi.org/10.2174/1570180053175133
DOI https://dx.doi.org/10.2174/1570180053175133 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Organelle Stress Sensors and Cell Death Mechanisms in Neurodegenerative Diseases
CNS & Neurological Disorders - Drug Targets Alterations in the Expression of Amyloid Precursor Protein Cleaving Enzymes mRNA in Alzheimer Peripheral Blood
Current Alzheimer Research The Therapeutic Potential of RNA Interference: Novel Approaches for Cancer Treatment
Current Pharmaceutical Biotechnology Glutamate Carboxypeptidase II in Diagnosis and Treatment of Neurologic Disorders and Prostate Cancer
Current Medicinal Chemistry The Potential Dual Effects of Anesthetic Isoflurane on Aβ-Induced Apoptosis
Current Alzheimer Research CXXC5 Associates with Smads to Mediate TNF-α Induced Apoptosis
Current Molecular Medicine Ubiquitin-Protein Ligases - Novel Therapeutic Targets?
Current Protein & Peptide Science Impaired Cerebral Autoregulation and Vasomotor Reactivity in Sporadic Alzheimer’s Disease
Current Alzheimer Research Microglia and Astrocytes in Alzheimer's Disease: Implications for Therapy
Current Neuropharmacology Progranulin Regulates Inflammation and Tumor
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Psychomotor Seizure Screening and in vitro Neuroprotection Assay of Hydrazones Derived from 2-Acetyl Thiophene
Central Nervous System Agents in Medicinal Chemistry Nanoparticle- and Liposome-carried Drugs: New Strategies for Active Targeting and Drug Delivery Across Blood-brain Barrier
Current Drug Metabolism Using Mass Spectrometry-Based Peptidomics to understand the Brain and Disorders such as Parkinson’s Disease and Schizophrenia
Current Topics in Medicinal Chemistry Metal Nanoparticles for the Treatment and Diagnosis of Neurodegenerative Brain Diseases
Current Pharmaceutical Design Cancer Nanotechnology: Emerging Role of Gold Nanoconjugates
Anti-Cancer Agents in Medicinal Chemistry S-Nitrosylation: Targets, Controls and Outcomes
Current Genomics Protein Kinase C-Related Kinase (PKN/PRK). Potential Key-Role for PKN1 in Protection of Hypoxic Neurons
Current Neuropharmacology Optimization and Assay of Antioxidant Potential of Two Penicillium spp. by Different Procedures
Current Biotechnology Diabetes Mellitus to Neurodegenerative Disorders: Is Oxidative Stress Fueling the Flame?
CNS & Neurological Disorders - Drug Targets Editorial (Thematic Issue: Linkage of Neurodegenerative Disorders with Other Health Issues – Volume I)
CNS & Neurological Disorders - Drug Targets